Rationale for short course primaquine in Africa to interrupt malaria transmission

Chi Eziefula, R Gosling, Jimee Hwang, Michelle Hsiang, Teun Bousema, Lorenz Von Seidlein, Chris Drakeley

    Research output: Contribution to journalArticle

    5 Downloads (Pure)

    Abstract

    Following the recent successes of malaria control in sub-Saharan Africa, the gametocytocidal drug primaquine needs evaluation as a tool to further reduce the transmission of Plasmodium falciparum malaria. The drug has scarcely been used in Africa because of concerns about its safety in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The evidence base for the use of primaquine as a transmission blocker is limited by a lack of comparable clinical and parasitological endpoints between trials. In March 2012, a group of experts met in London to discuss the existing evidence on the ability of primaquine to block malaria transmission, to define the roadblocks to the use of primaquine in Africa and to develop a roadmap to enable its rapid, safe and effective deployment. The output of this meeting is a strategic plan to optimize trial design to reach desired goals efficiently. The roadmap includes suggestions for a series of phase 1, 2, 3 and 4 studies to address specific hurdles to primaquines deployment. These include ex-vivo studies on efficacy, primaquine pharmacokinetics and pharmacodynamics and dose escalation studies for safety in high-risk groups. Phase 3 community trials are proposed, along with Phase 4 studies to evaluate safety, particularly in pregnancy, through pharmacovigilance in areas where primaquine is already deployed. In parallel, efforts need to be made to address issues in drug supply and regulation, to map G6PD deficiency and to support the evaluation of alternative gametocytocidal compounds.
    Original languageEnglish
    Pages (from-to)1-15
    Number of pages15
    JournalMalaria Journal
    Volume11
    Issue number360
    DOIs
    Publication statusPublished - 2012

    Fingerprint Dive into the research topics of 'Rationale for short course primaquine in Africa to interrupt malaria transmission'. Together they form a unique fingerprint.

  • Cite this

    Eziefula, C., Gosling, R., Hwang, J., Hsiang, M., Bousema, T., Von Seidlein, L., & Drakeley, C. (2012). Rationale for short course primaquine in Africa to interrupt malaria transmission. Malaria Journal, 11(360), 1-15. https://doi.org/10.1186/1475-2875-11-360